ClinicalTrials.gov
public full text
Public Domain
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2 inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD and/or RP2D, and preliminary anti- cancer activity in Chinese subjects with advanced solid tumors and in Chinese subjects with advanced or metastatic EGFR-mutant NSCLC.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer#861202
- Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies#349943
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma#828118
- A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors#1125253
- Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors#824951
Record · ID 1031604
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive